Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1016/j.aohep.2019.08.001 http://hdl.handle.net/11449/197553 |
Resumo: | Introduction and objectives: Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir ( SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results: 3939 patients (60% males, mean age 58 +/- 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. |
id |
UNSP_95c1ef32ebced65ba0846c0c2c5b1c33 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/197553 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from BrazilChronic hepatitis CDirect antiviral agentsHepatic fibrosisCirrhosisIntroduction and objectives: Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir ( SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results: 3939 patients (60% males, mean age 58 +/- 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.Fundacao Hosp Estadual Acre, Rio Branco, AC, BrazilHosp Portugues, Salvador, BA, BrazilUniv Estadual Paulista, Botucatu, SP, BrazilUniv Fed Juiz de Fora, Juiz De Fora, MG, BrazilUniv Fed Rio de Janeiro, Rio De Janeiro, RJ, BrazilInst Neurol Curitiba SC Ltda, Curitiba, Parana, BrazilUniv Fed Sao Paulo, Sao Paulo, SP, BrazilUniv Fed Alagoas, Maceio, AL, BrazilAmbulatorio Hepatites Virais Prefeitura Municipal, Criciuma, SC, BrazilHosp Albert Einstein, Sao Paulo, SP, BrazilCtr Referencia Especialidades Cent Ribeirao Preto, Ribeirao Preto, SP, BrazilUniv Fed Rio Grande do Sul, Porto Alegre, RS, BrazilCTA Sae Ambulatorio Hepatites Virais, Maringa, PR, BrazilUniv Fed Goias, Goiania, Go, BrazilInst Infectol Emilio Ribas, Sao Paulo, SP, BrazilHosp Base Dist Fed, Brasilia, DF, BrazilAmbulatorio Hepatites Virais Feira Santana Prefei, Feira De Santana, BA, BrazilUniv Fed Paraiba, Joao Pessoa, Paraiba, BrazilUniv Sao Paulo, Sao Paulo, SP, BrazilUniv Estadual Paulista, Botucatu, SP, BrazilElsevier B.V.Fundacao Hosp Estadual AcreHosp PortuguesUniversidade Estadual Paulista (Unesp)Univ Fed Juiz de ForaUniversidade Federal do Rio de Janeiro (UFRJ)Inst Neurol Curitiba SC LtdaUniversidade Federal de São Paulo (UNIFESP)Univ Fed AlagoasAmbulatorio Hepatites Virais Prefeitura MunicipalHosp Albert EinsteinCtr Referencia Especialidades Cent Ribeirao PretoUniv Fed Rio Grande do SulCTA Sae Ambulatorio Hepatites ViraisUniversidade Federal de Goiás (UFG)Inst Infectol Emilio RibasHosp Base Dist FedAmbulatorio Hepatites Virais Feira Santana PrefeiUniv Fed ParaibaUniversidade de São Paulo (USP)Oliveira Lobato, Cirley Maria deCodes, LianaSilva, Giovanni Faria [UNESP]Meirelles Souza, Aecio FlavioMoraes Coelho, Henrique SergioAlves Pedroso, Maria LuciaParise, Edison RobertoTojal de Barros Lima, Leila Maria SoaresBorba, Luiz AugustoEvangelista, Andreia SilvaFontes Rezende, Rosamar EuliraCheinquer, HugoOba Kuniyoshi, Aline SatieAires, Rodrigo SebbaDias Quintela, Eloiza HelenaCosta Mendes, Liliana SampaioVosqui Nascimento, Fabio CarneiroMoraes de Medeiros Filho, Jose EymardCardoso Gomes Ferraz, Maria LuciaAbdala, EdsonBittencourt, Paulo LisboaBrazilian Real-Life Study HCV Trea2020-12-11T03:29:21Z2020-12-11T03:29:21Z2019-11-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article849-854http://dx.doi.org/10.1016/j.aohep.2019.08.001Annals Of Hepatology. Madrid: Elsevier Espana, v. 18, n. 6, p. 849-854, 2019.1665-2681http://hdl.handle.net/11449/19755310.1016/j.aohep.2019.08.001WOS:000496943100012Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAnnals Of Hepatologyinfo:eu-repo/semantics/openAccess2024-08-14T17:36:53Zoai:repositorio.unesp.br:11449/197553Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:36:53Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
title |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
spellingShingle |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil Oliveira Lobato, Cirley Maria de Chronic hepatitis C Direct antiviral agents Hepatic fibrosis Cirrhosis |
title_short |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
title_full |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
title_fullStr |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
title_full_unstemmed |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
title_sort |
Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil |
author |
Oliveira Lobato, Cirley Maria de |
author_facet |
Oliveira Lobato, Cirley Maria de Codes, Liana Silva, Giovanni Faria [UNESP] Meirelles Souza, Aecio Flavio Moraes Coelho, Henrique Sergio Alves Pedroso, Maria Lucia Parise, Edison Roberto Tojal de Barros Lima, Leila Maria Soares Borba, Luiz Augusto Evangelista, Andreia Silva Fontes Rezende, Rosamar Eulira Cheinquer, Hugo Oba Kuniyoshi, Aline Satie Aires, Rodrigo Sebba Dias Quintela, Eloiza Helena Costa Mendes, Liliana Sampaio Vosqui Nascimento, Fabio Carneiro Moraes de Medeiros Filho, Jose Eymard Cardoso Gomes Ferraz, Maria Lucia Abdala, Edson Bittencourt, Paulo Lisboa Brazilian Real-Life Study HCV Trea |
author_role |
author |
author2 |
Codes, Liana Silva, Giovanni Faria [UNESP] Meirelles Souza, Aecio Flavio Moraes Coelho, Henrique Sergio Alves Pedroso, Maria Lucia Parise, Edison Roberto Tojal de Barros Lima, Leila Maria Soares Borba, Luiz Augusto Evangelista, Andreia Silva Fontes Rezende, Rosamar Eulira Cheinquer, Hugo Oba Kuniyoshi, Aline Satie Aires, Rodrigo Sebba Dias Quintela, Eloiza Helena Costa Mendes, Liliana Sampaio Vosqui Nascimento, Fabio Carneiro Moraes de Medeiros Filho, Jose Eymard Cardoso Gomes Ferraz, Maria Lucia Abdala, Edson Bittencourt, Paulo Lisboa Brazilian Real-Life Study HCV Trea |
author2_role |
author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Fundacao Hosp Estadual Acre Hosp Portugues Universidade Estadual Paulista (Unesp) Univ Fed Juiz de Fora Universidade Federal do Rio de Janeiro (UFRJ) Inst Neurol Curitiba SC Ltda Universidade Federal de São Paulo (UNIFESP) Univ Fed Alagoas Ambulatorio Hepatites Virais Prefeitura Municipal Hosp Albert Einstein Ctr Referencia Especialidades Cent Ribeirao Preto Univ Fed Rio Grande do Sul CTA Sae Ambulatorio Hepatites Virais Universidade Federal de Goiás (UFG) Inst Infectol Emilio Ribas Hosp Base Dist Fed Ambulatorio Hepatites Virais Feira Santana Prefei Univ Fed Paraiba Universidade de São Paulo (USP) |
dc.contributor.author.fl_str_mv |
Oliveira Lobato, Cirley Maria de Codes, Liana Silva, Giovanni Faria [UNESP] Meirelles Souza, Aecio Flavio Moraes Coelho, Henrique Sergio Alves Pedroso, Maria Lucia Parise, Edison Roberto Tojal de Barros Lima, Leila Maria Soares Borba, Luiz Augusto Evangelista, Andreia Silva Fontes Rezende, Rosamar Eulira Cheinquer, Hugo Oba Kuniyoshi, Aline Satie Aires, Rodrigo Sebba Dias Quintela, Eloiza Helena Costa Mendes, Liliana Sampaio Vosqui Nascimento, Fabio Carneiro Moraes de Medeiros Filho, Jose Eymard Cardoso Gomes Ferraz, Maria Lucia Abdala, Edson Bittencourt, Paulo Lisboa Brazilian Real-Life Study HCV Trea |
dc.subject.por.fl_str_mv |
Chronic hepatitis C Direct antiviral agents Hepatic fibrosis Cirrhosis |
topic |
Chronic hepatitis C Direct antiviral agents Hepatic fibrosis Cirrhosis |
description |
Introduction and objectives: Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir ( SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results: 3939 patients (60% males, mean age 58 +/- 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-11-01 2020-12-11T03:29:21Z 2020-12-11T03:29:21Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.aohep.2019.08.001 Annals Of Hepatology. Madrid: Elsevier Espana, v. 18, n. 6, p. 849-854, 2019. 1665-2681 http://hdl.handle.net/11449/197553 10.1016/j.aohep.2019.08.001 WOS:000496943100012 |
url |
http://dx.doi.org/10.1016/j.aohep.2019.08.001 http://hdl.handle.net/11449/197553 |
identifier_str_mv |
Annals Of Hepatology. Madrid: Elsevier Espana, v. 18, n. 6, p. 849-854, 2019. 1665-2681 10.1016/j.aohep.2019.08.001 WOS:000496943100012 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Annals Of Hepatology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
849-854 |
dc.publisher.none.fl_str_mv |
Elsevier B.V. |
publisher.none.fl_str_mv |
Elsevier B.V. |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128206536966144 |